OTC: UMEW

Investing upstream
in sustainable flight.

UMeWorld is building a biotechnology-enabled SAF feedstock platform designed around circular inputs, refinery compatibility, and scalable infrastructure.

A focused aviation-energy platform.

Our strategy is centered on a structural constraint in sustainable aviation fuel: the availability of scalable, cost-effective, high-quality lipid feedstock. UMeWorld applies proprietary enzymatic technology to upgrade waste-derived lipid streams into refinery-compatible intermediates.

Project Verdant is the planned commercial-scale expression of that platform: a phased Renewable Aviation Fuels Hub in Malaysia combining proven HEFA production with proprietary microbial-oil development. FGE NexantECA has been engaged to independently assess Phase 1 before engineering and project financing.

Why UMeWorld.

A differentiated technology platform positioned at the upstream bottleneck of a growing SAF value chain.

01

Proprietary Platforms

Enzymatic upgrading and other proprietary biotechnology advancements create a defensible technical foundation across waste-lipid sourcing and conditioning.

02

Mandated Demand

SAF adoption frameworks globally and regulatory regimes create decades-long mandated demand for sustainable aviation fuels.

03

Feedstock Flexibility

Through our proprietary biotechnology platforms, we are able to use a substantial range of feedstocks to create high-value SAF intermediaries. We aren’t constrained by the used cooking oil supply bottlenecks plaguing much of the SAF industry.

04

Independent Validation

FGE NexantECA is conducting a technical and commercial feasibility assessment of Project Verdant Phase 1.

Platform indicators.

Selected facts from UMeWorld’s current market disclosures and Project Verdant development strategy.

MarketOTC: UMEW

UMeWorld Inc. trades on OTC Markets under the ticker UMEW.

Phase 1 target200,000 MTPA

Approximate annual SAF production target, subject to feasibility, engineering, financing, permitting, construction, and other approvals.

Current milestoneQ3 2026

Target completion period for the independent feasibility study before the planned FEED stage.

Investor resources.

Access current market information and U.S. securities filings from primary sources.